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Abstract
The prion diseases are rare and invariably fatal neurodegenerative diseases characterized 
by a unique, protein‐only pathogenesis. Mechanistically, the prion diseases result from the 
coerced conversion of a protease‐sensitive form of the cellular prion protein (PrPC) into 
a protease‐resistant infectious form (PrPres). This chapter reviews the past, present, and 
potentially future prion disease treatment strategies. This chapter begins with an intro‐
duction to prion diseases, the misfolding of prion proteins and what is known about this 
process, and then proceeds to discuss approaches for treatments. Regarding approaches 
to treat prion diseases, we discuss (1) small molecule inhibitors, (2) antiprion protein anti‐
bodies, (3) prion gene disruption, (4) targeting of the unfolded protein response, and (5) 
heterologous prion proteins. We elaborate on using heterologous prion proteins to treat 
prion diseases, as this is an area that we are pursuing. The chapter ends with thoughts on 
the future direction of prion disease treatment strategies and how these strategies might be 
applicable to other neurodegenerative diseases involving protein misfolding. The increas‐
ing awareness of the role of protein misfolding in many neurodegenerative processes 
makes the development of an effective treatment strategy for prion diseases a high priority.
Keywords: prion, treatment, CJD, GSS, PrPres, PrPC, heterologous prion proteins, protein 
misfolding diseases, neurodegenerative disorders
1. Introduction
Prion diseases, or transmissible spongiform encephalopathies (TSEs), are unique, fatal neu‐
rodegenerative diseases with infectious, genetic, or sporadic causes. Prion diseases affect 
humans (e.g. Creutzfeldt‐Jakob disease [CJD], Gerstmann‐Straussler‐Scheinker syndrome 
[GSS], and fatal familial insomnia [FFI]) and nonhumans (e.g. bovine spongiform encephalop‐
athy [BSE] of cattle, chronic wasting disease [CWD] of cervids, and scrapie of sheep and goats. 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Irrespective of affected species, prion diseases result in progressive neurocognitive decline fol‐
lowing a long incubation period. No effective prion disease treatments exist and most human 
patients die within 14 months following diagnosis [1]. Notably, many of the fundamental 
characteristics of prion diseases, including the molecular and biochemical mechanisms under‐
lying the formation, accumulation, and cell‐to‐cell infectivity of misfolded protein and the role 
of glial‐mediated neuroinflammation aligns prion diseases with more common human neuro‐
degenerative conditions, including Alzheimer's, Parkinson's, and Huntington's diseases.
In the mouse, the prion protein is encoded by the Prnp gene. The nascent 254 amino acid long 
peptide is then posttranslationally cleaved at its N and C terminus to produce the final 210 
amino acid long protein [2–4]. Structurally, the prion protein is characterized by a disordered 
aminoterminal tail and a globular C‐terminal domain consisting of three α‐helices and two anti‐
parallel β‐sheets [5, 6]. It is anchored to the outer cell surface membrane via a glycosylphospha‐
tidylinositol (GPI) anchor, which helps tether the protein to the outer cell surface membrane [7].
The hallmark event in the prion disorders is the misfolding of the normal cellular prion protein 
(denoted PrPC) into a misfolded isoform (commonly denoted as PrPres or PrPSc). In its normal 
form, PrPC is a monomeric or dimeric protein with abundant alpha helical content, whereas the 
misfolded variant PrPres is aggregated with a β‐pleated sheet rich conformation [8, 9]. In addition 
to its structural differences, PrPres is characterized by resistance to protease and chemical disin‐
fection [10]. Although the entirety of the process has not been described, it is widely believed that 
PrPres replication results from the induced misfolding of PrPC through a nucleation‐dependent 
polymerization mechanism [11]. This process is included in the model presented in Figure 1.
In the pathogenesis of prion diseases, the formation of PrPres is generally believed to be a key 
event in the disease initiation. Owing to its specificity as a marker of tissue infectivity, PrPres 
is the most commonly used prion disease diagnostic marker. Although the inciting cause 
(i.e. PrPres formation) and neuropathologic consequences of prion disease (i.e. gliosis, synap‐
tic dysfunction, spongiosis, and neuronal loss) are well characterized, the mechanism(s) by 
Figure 1. A proposed model of heterologous prion protein treatment in the misfolding, nucleation, and formation of 
amyloid. In the presence of misfolded PrPres, the normal cellular prion protein (PrPc) is induced to misfold. This cycle 
of misfolding repeats leading to seeds of misfolded oligomers and amyloid deposits. Our studies demonstrate that 
heterologous prion proteins inhibit this process. We propose that heterologous prion proteins bind directly to PrPC and 
PrPres to block seed and amyloid formation.
Prion - An Overview28
which the former results in the latter remain unknown. However, it is likely that misfolded 
PrPC has direct/indirect toxic properties as, as PrPC does not appear to be detrimental [12].
The conversion of PrPC to PrPres is a highly specific process of templated conversion requiring 
direct interaction between the normal and abnormal forms of the protein [13]. The efficiency of 
this conversion is predicated upon a number of specific reaction conditions, including the sec‐
ondary structure of PrPres, homology of the primary and secondary structures between PrPC 
and PrPres, and the architecture of the PrPC‐PrPres complex [14, 15]. Increased contact between 
PrPC‐PrPres at residue 129 and the relative rigidity of the β2‐α2 loops in PrPC are two important 
factors in mediating the efficiency of PrPres formation and TSE susceptibility [15–17]. In addi‐
tion to steric factors, the formation of PrPres is favored by destabilization of PrPC as a number of 
destabilizing pathogenic mutations in PrP are linked with increasing misfolding rates [18–20].
The presence and primary structure of host PrPC are major determinants in conferring suscep‐
tibility to prion disease infection. This is most expressly evident by work demonstrating that 
transgenic mice lacking PrPC are conferred resistance to prion infection [21]. Beyond simple 
PrPC expression, the degree of sequence homology between infecting prion and host PrPC 
plays a significant role in determining the efficiency of prion infection and prion replication 
[22]. Moreover, differences in primary sequence between host PrPC and infectious PrPres have 
been proposed to underlie the species barrier that mitigates cross species prion infection as 
well as prion strains [23–25]. The importance of prion structure extends beyond simple amino 
acid homology and is also dependent upon secondary structural variations, including differ‐
ences in loop/turn structures [23, 26]. In light of complementary in vitro and in vivo work, 
it appears as though the middle third region of the prion protein is particularly important 
for the autocatalytic conversion of PrPC to PrPres [27]. The potential clinical relevance of PrPC 
sequence is demonstrated by work revealing that polymorphisms in this area of the protein 
can confer prion disease resistance, as mice expressing a variant PrP containing amino acid 
substitutions in the β2‐α2 loop were resistant to prion infection [28].
Given studies that have revealed the pathogenic importance of a precisely formed PrPC‐PrPres 
complex, it seems reasonable to investigate whether interference with this complex might 
have therapeutic potential. This approach is best described by Singh and Udgaonkar in their 
comprehensive review on PrP misfolding, namely to test whether or not “…any ligand, 
whether small or large, that binds to the native conformation of the [PrPC] protein would sta‐
bilize that state and can therefore be expected to decrease the native‐state dynamics that drive 
misfolding [29].” Support for such an approach has been validated by antibody‐based studies, 
which have stabilized the α1 region of PrPC and prevented prion disease in animals [30, 31].
In this chapter, we review past, present, and potential future strategies to treat prion diseases.
2. Small molecule inhibitors to treat prion diseases
There are a number of small molecules that have proposed as prion therapeutics, including 
that either inhibit the misfolding of PrPC or promote the clearance of PrPres. In general, small 
molecule compounds can be segregated according to their method of action into compounds 
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that either inhibit the misfolding of PrPC (potentially through stabilization) promote the clear‐
ance of PrPres. Over the past two decades, many small molecules have been evaluated for their 
in vitro or in vivo antiprion efficacy.
Of the most commonly examined small molecule candidate therapies, many have not stood up 
to scrutiny when their in vitro efficacy was tested in vivo. This includes quinacrine, pentosan 
poylsufate, Congo red, amphotericin B, anthracyclines, and memantine [32–39]. Moreover, 
a subset of these compounds has been shown to extend the lives of prion‐infected animals 
[40–42]. However, as noted by Caughey et al., the “clinical applicability of these compounds 
is severely limited by a lack of activity when administered after the onset of clinical signs of 
disease, poor bioavailability to the brain, and/or high toxicity [42–46].” Despite the incremen‐
tal progress in the field, efforts to more efficiently identify and screen test compounds for 
antiprion activity are ongoing. Early work by Pruisner et al. searched the Available Chemicals 
Directory for molecules that inhibit prion replication based upon prior studies, identified a 
number of a family of compounds (pyridine dicarbonitriles) that showed in vitro efficacy 
in inhibiting prion replication [47, 48]. Follow‐up studies by Reddy et al., who, through the 
design, synthesis, and screening of a series of related compounds, identified an additional 
compound that demonstrated efficacy at mitigating PrPres formation [49]. Most recently, 
Ferriera et al. describe the in silico and in vitro identification and screening of new small 
organic antiscrapie compounds that decreased PrPres accumulation and inhibit PrP aggrega‐
tion [46]. Mechanistically, one of the most intriguing families of antiprion compounds is chem‐
ical chaperones. Chaperones are cellular constituents that interact with, stabilize, and assisting 
in the proper folding of nonfolded proteins [50]. When used pharmacologically, chaperones 
are small compounds that bind to proteins and either induce their refolding or stabilize their 
structure. Specific chaperones demonstrating in vitro and/or in vivo efficacy in prion disease 
systems including (along with their mechanism of action): trimethylamine N‐oxide, glycerol, 
dimethyl sulfoxide (protein stabilization by altering solvent properties), and bile salts [51, 52].
3. Antiprion antibodies to treat prion diseases
Other treatment strategies for prion diseases have been attempted including vaccination 
and immunotherapy, but these strategies have had limited success [53]. Nonetheless, there 
have been several promising studies gaining insights into this approach and its potential. To 
reduce redundancies, we refer the interested reader to the chapter entitled “Immunobiology 
of Prion Diseases” for more information on this topic.
4. Prion gene disruption to treat prion diseases
Since the cellular prion protein is not essential for life but required for prion disease [54, 55], 
several groups have worked to develop and test strategies that disrupt normal cellular prion 
proteins, PrPC. With this in mind, a recent treatment strategy used lentivirus vectors that 
expressed silencing RNAs directed against the cellular form of the prion protein [56]. These 
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lentiviral vectors were employed to transduce mouse embryonic stem cells and the resultant 
transduced embryonic stem cells used to create chimeric mice expressing various levels of the 
silencing RNAs. After infection of these mice with scrapie, mice that were highly chimeric 
for the transgene and that showed reduced PrPC expression in the brain showed increased 
survival times. Similarly, Mallucci et al. generated an adult‐onset PrP knockout mouse model 
with delayed, neuron‐specific deletion of PrPC, which mitigated the clinical and neuropatho‐
logic consequences of prion disease [57, 58]. In another study, the same group used RNAi‐
driven gene silencing to reduce PrPC expression. Using lenti‐shRNA directed against PrPC, 
treated mice experienced a significant downregulation of PrPC expression and a delay in 
prion disease progression [59]. Thus, strategies that reduce or eliminate PrPC using inhibitory 
RNAs show promise as a treatment for prion diseases.
An alternative approach to reducing PrPC expression is to edit the gene using Zn‐finger nucle‐
ases (ZFN), transcription activator‐like effector nucleases (TALEN), or clustered regularly 
interspaced short palindromic repeats (CRISPR) gene editing systems. Indeed, mice, bovine 
and goat prion genes have been targeted using these approaches [60–62] to produce disease 
resistant animals, and at least one patent has been filed for gene editing of prion genes in 
animals [63].
5. Target the unfolded protein response to treat prion diseases
The pivotal event in prion disease pathogenesis is the formation and accumulation of mis‐
folded PrPres in the brain as it initiates a pathologic cascade of glial activation, neuronal hypo‐
metabolism, and apoptotic neuronal loss. An increasing body of work indicates that PrPres 
triggers this pathology, in part, through the activation of the unfolded protein response (UPR) 
[64]. The UPR is a two‐phase, cytoprotective cascade of the endoplasmic reticulum (ER) that 
is initiated by misfolded or aggregated protein, and it seeks to resolve cellular and ER stress. 
In the initial adaptive phase of the UPR, misfolded protein stimulates one (or more) of three 
sensing proteins: (1) PERK (protein kinase RNA‐like ER kinase), (2) IRE1α (inositol‐requiring 
protein 1), and/or (3) ATF6 (activating transcription factor‐6). Subsequent homodimerization 
of two of these proteins (PERK and IRE1α) results in the phosphorylation and activation of 
intermediate messengers, including eIF2α (eukaryotic initiation factor 2 alpha), ATF4 (acti‐
vating transcription factor), and XBP1 (X‐box folding protein). The end result of the adaptive 
phase of the UPR is an attenuation of protein synthesis, an increased synthesis of ER chap‐
erones, and a mitigation of ER protein processing [65, 66]. However, if these initial adaptive 
efforts fail, the UPR transitions to a second, apoptotic phase involving the activation of cas‐
pases 3, 6, 7, and 8.
Previous work has demonstrated involvement of both phases of the UPR in human and 
rodent prion disease [67, 68]. In addition to triggering apoptosis, it is increasing clear that the 
UPR is able to induce the deleterious, glial‐mediated inflammatory response that is character‐
istic of both prion and other neurodegenerative diseases [69]. Specifically, Moreno et al. have 
shown that prion replications results in unchecked eIF2α activation that contributes to syn‐
aptic failure, neuronal loss, and clinical deficits in prion‐infected mice [70]. However, the role 
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of the UPR in human prion disease is less clear. Although Hetz et al. demonstrated increased 
levels of ER stress associated with misfolded protein in the brains of human patients with 
sporadic or variant CJD [71], subsequent immunohistochemical studies examining the brains 
of human patients with CJD for activated forms of PERK and eIF2α have failed confirm con‐
sistent involvement of the UPR [72].
Despite the inconclusive mechanistic data linking the UPR with prion disease pathogene‐
sis, a small number of groups have examined the efficacy of therapeutic strategies directed 
at mitigating its activation. The therapeutic potential of targeting the UPR pathway is best 
demonstrated by work performed by Mallucci and Moreno. In their initial studies, they 
report that genetic mitigation of eIF2α activation decreases synaptic loss and neuronal loss 
in prion‐infected mice [70]. Moreover, in follow‐up work they demonstrate that upstream 
blockade of UPR activation through pharmacological inhibition of the activation of PERK 
reverses cognitive deficits and prevents clinical disease in prion‐infected mice [67]. A smaller 
body of work has revealed that pharmacologic inhibition of the UPR using the neuroprotec‐
tive, antiapoptotic bile acids tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid 
(UDCA), results in decreased levels of activated eIP2α in organotypic cerebellar slices as well 
as decreased neuroinflammation and prolonged survival in mice. The reported benefits of 
bile acids result, in part, from their ability to inhibit the UPR activation across all three sens‐
ing pathways as reflected by lower levels of phosphorylated eIF2α, ATF4, PERK, ATF6, and 
IRE1α [73–76].
6. Heterologous prion proteins to treat prion diseases
The concept of heterologous prion proteins (HetPrP) as potential therapeutics is based on 
a body of research, including studies performed in cell free, cell culture, and animal mod‐
els, in which prion proteins from different species were allowed to interact. Horiuchi et al. 
demonstrate that inclusion of a heterologous species PrPc in a cell‐free conversion system 
was capable of interfering with the formation of PrPres between two homologous species 
[24]. When they divide the process of PrPres formation into two steps, namely initial binding 
between PrPC and PrPres followed by acquisition of protease resistance, the interfering effect 
of HetPrP appears to occur during the latter [24]. Further, the expression of hamster prion 
protein (HaPrP) in scrapie‐infected mouse cells in vitro lead to near complete elimination 
of PrPres [77] supporting a role for heterologous HaPrP in either inhibiting PrPres production 
or enhancing its clearance. Moreover, the induced expression rabbit prion proteins in scra‐
pie‐infected mouse cells led to substantially less PrPres as compared to mouse cells that do 
not express rabbit prion proteins, supporting a role for rabbit prion proteins interfering with 
mouse PrPres formation [23].
In our work, we extended these in vitro observations into the mouse using the rocky moun‐
tain laboratories (RML)‐Chandler strain of scrapie and HetPrP therapy using bacterially 
expressed and purified recombinant HaPrP amino acids 23‐231 [78]. For this study, mice 
were intracerebrally inoculated with an RML‐Chandler strain brain homogenate combined 
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with either recombinant HaPrP or vehicle control. The following day, mice were treated with 
HaPrP orally. We assessed the effect of HaPrP dosage using two treatment groups, includ‐
ing a high dose of recombinant protein (0.7 mg/ml, high dose) and a low dose (0.35 mg/ml). 
Lastly, two control groups were included, those being a mock treatment group comprised of 
mice that were infected and treated with vehicle only, and mice that were not infected and 
not treated. We assessed the impact of treatment on clinical disease by evaluating mice daily 
following infection, weekly during the first months and then daily in later months for signs 
of scrapie‐related symptoms including decreased motility, flattened stature, ataxic gait, hind 
limb paresis, dull eyes, weight loss, and kyphosis.
Treatment with the high dose HaPrP effectively and significantly delayed the onset of clinical 
symptoms, and prolonged survival compared to the vehicle‐treated animals [78]. Moreover, 
when the study was terminated at 452 days postinfection, half of the high‐dose‐treated ani‐
mals were still free of scrapie symptoms. Figure 2 shows the survival times.
In addition to abrogating the clinical signs of prion disease, mice receiving the high‐dose of 
HaPrP, compared to mice treated with a low dose of HaPrP or with vehicle only, accumu‐
lated significantly less PrPres in both brain and spleen. Furthermore, HaPrP partially mitigated 
Figure 2. Treatment with heterologous recombinant HaPrP prolonged survival. Kaplan‐Meier plots showing the 
survival times of mock‐treated (orange, n = 5), low‐dose‐treated (blue, n = 5), high‐dose‐treated mice (purple, n = 6) and 
uninfected (red, n = 10). We tested for differences between groups using a modified version of the Gehan‐Wilcoxon test 
and found a statistically significant difference between the mock infected group and the high‐dose group (p = 0.0348).
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the neuropathologic consequences of prion infection as high‐dose‐treated animals showed 
a trend towards fewer activated astrocytes as revealed by immunohistochemistry for glial 
fibrillary acidic protein and less severe neuropil spongiosis in total brain and highly signifi‐
cant reductions in the thalamus.
Although we demonstrated that treatment with HetPrPC inhibits both the formation of 
PrPres and the clinical consequences of prion infection, the mechanism underlying this phe‐
nomenon is not known. We think that HetPrP binds to both PrPres and PrPC and blocks 
the production and elongation of PrPres chains and amyloid formation. This is modeled in 
Figure 1.
The work of Horiuchi et al. offers two possible mechanistic models for this interference, based 
upon number and type of binding sites for PrPC on PrPres [24]. They posit in a “one binding 
system,” that the binding of HetPrP to a growing PrPres oligomer creates an aggregate that 
is incapable of generating the steric interactions necessary for the continued production of 
PrPres. Alternately, they propose in a “two binding system” that the growing PrPres oligomer 
contains two binding sites, namely a conversion‐inducing site and a nonconverting site. In 
this two‐site system, HetPrP interferes with the formation of PrPres by binding and blockading 
conversion site without blocking the nonconverting site.
In addition to biochemical mechanisms described, it is possible that the protective effect of 
HetPrP in our study resulted from an evoked immune response that impacted PrPres forma‐
tions. However, our data do not support this hypothesis. By western blot analysis of serum 
from study mice, we did not detect the presence of antihamster PrP antibodies in treated 
compared to control animals. Lastly, it is important to note that because mice were simultane‐
ously intracerebrally inoculated with both scrapie prions and HaPrP, it is quite likely that the 
HaPrP in the inoculum served to inactivate the scrapie prion by binding to PrPres and forming 
an inactive complex due to sequence incongruence.
It is increasingly apparent that HetPrP treatment safely inhibits the PrPC to PrPres conversion 
process. In vitro and in vivo studies render feasible the prospect of treating human prion 
diseases with HetPrP. While demonstrating efficacy, in our study the treatment regime used 
(intracerebral instillation of HetPrP at the time of infection followed by oral ingestion of het‐
erologous PrPC) which is not ideal for treating patients with existing prion disease. Delivery 
via intracerebral injection is certainly not anticipated to allow HetPrP to make contact with 
and inactivate all PrPres in the system. As such, future studies are needed to develop more 
practical HetPrP delivery modalities as well as to evaluate potentially more effective HetPrP 
sequences.
While a wide range of mammal species are susceptible to prion infection, the efficiency of 
interspecies transmission is varied and governed by a “species barrier,” the integrity of which 
is inversely proportional to the strength of the interaction between host PrPC and incoming 
PrPres. Interestingly, rabbits have been shown to be unusually resistant to prion disease inoc‐
ulation, as attempts to transmit CJD, Kuru, sheep scrapie, TME, and mouse‐adapted scra‐
pie to rabbits failed [79, 80]. While subsequent groups have confirmed that the rabbit is not 
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 absolutely resistant or prion infection, there is general agreement that they are only minimally 
susceptible [81, 82]. The degree of primary sequence homology is important in determining 
the robustness of the species barrier. The rabbit prion protein shows relatively low sequence 
homology to other species prion proteins. Based upon this work, we propose that a rabbit 
PrP‐based HetPrP treatment strategy may be more effective than HaPrP at inhibiting prion 
disease.
While we used IC injection of HetPrP in our study, the clinical evolution of this approach 
necessitates a more effective and simpler means of delivery. One such approach could be 
delivery via the bloodstream and use blood vessels to efficiently deliver HetPrP to all areas 
of the brain. In addition, it may be possible to use peptides derived from HetPrP rather than 
whole proteins. Indeed Chabry et al. showed in vitro inhibition of PrP conversation with 
synthetic peptides derived from mouse and hamster PrP [83, 84]. Another such possibility for 
HetPrP treatment is the adoption of a gene therapy‐based approach using lentiviral vectors. 
Thus, further studies are warranted to optimize both the form of HetPrP as well as its mode 
of delivery.
In related studies, other groups have found promising therapeutic results as well. Meier 
et al. engineered PrPC fused to immunoglobulin Fcgamma, termed PrP‐Fc(2) [85]. Wild‐
type mice expressing PrP‐Fc(2) and subsequently infected with scrapie prions showed 
delayed PrPres accumulation and onset of disease [85]. In follow‐up studies, they further 
showed that expression of PrP‐Fc(2) transduced by a lentiviral vector at 170 days postin‐
fection was able to reduce prion infectivity by 3–4 logs [86]. Toupet et al. created a recom‐
binant lentiviral vector that transduces expression of a dominant negative mouse prion 
protein that recapitulates sheep PrPQ171R and human PrPE219K polymorphisms associ‐
ated with prion disease resistance [87]. They showed that chronic injection of this vector 
directly into the brains of prion disease infected mice led to reduced astrocytic gliosis and 
extended survival [87]. Moreover, Soto et al. designed beta sheet breaker peptides cor‐
responding to the conserved region of PrP 115‐122 that is thought to play a central role in 
conversion of PrPC to PrPres [88–91]. These beta sheet peptides partly reversed PrPres to PrPc 
in vitro, and when mixed with scrapie prions and injected into mice, decreased infectivity 
by 90–95% [88]. Thus, multiple strategies have been developed and tested in mice that use 
prion proteins or related peptides to target and reduce prion infectivity and have demon‐
strated efficacy.
7. Potential future strategies to treat prion diseases
Understanding pathogenesis is key to developing new therapies for prion diseases. For exam‐
ple, we [92, 93] and others have gained insights into prion disease pathogenesis by study‐
ing in changes in gene expression that occur during the disease process. These expression 
alterations provide insights to underlying pathological processes, and key mediators of these 
processes might be targeted in future prion treatment strategies. Another example comes 
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from Hetz et al., who determined in a scrapie infected cell culture system that PrPsc toxicity 
and apoptosis induction was associated in an increase in an endoplasmic reticulum resident 
enzyme caspase‐12, and a corresponding increase in caspase‐12 was also seen in humans 
affected by CJD [94]. With this knowledge of a key process in pathogenesis, they were able to 
inhibit apoptosis by overexpression of a catalytic mutant of caspase‐12 [94]. In another set of 
studies, the 37 kDa/67 kDa laminin receptor LPR/LR was targeted based on knowledge that 
LPR/LR is a cell surface receptor for PrPc [95] and required for PrPres propagation in scrapie‐
infected cells [96]. Zuber et al. created and infused single‐chain Fv antibodies directed against 
LPR/LR into mice just prior to inoculation with scrapie prions and weekly afterwards, and 
found an ~40% reduction in PrPres in spleen [97]. In similar experiments, Pflanz et al. injected 
lentiviral vectors that transduce small interfering RNAs directed against LPR/LR precursor 
mRNA into the brains of mice, then infected them with scrapie, and found a 41% reduc‐
tion in PrPres and prolongation of the preclinical phase [98]. Thus, gaining understanding of 
the molecular event underlying prion disease pathogenesis can identify potential targets for 
future prion disease therapeutics.
Moving forward to a viable treatment and cure for prion diseases in humans will likely involve 
a combination of therapies. For example, this might involve a combination of approaches 
such as gene editing to create disease resistant prion gene alleles, a drug that inhibits apopto‐
sis, a small molecule that stabilizes PrPc and regular injections of heterologous prion proteins 
that bind and clear nascent PrPres.
Importantly, strategies that work for treating prion diseases may also be effective when applied 
to other neurodegenerative diseases that involve protein misfolding, such as Alzheimer's dis‐
ease and Huntington's chorea. There is increasing evidence of underlying similarities in the 
pathogenesis of protein misfolding neurodegenerative diseases. Hence, similar cure strate‐
gies may be feasible.
8. Conclusion
In conclusion, an ever‐expanding understanding of basic prion pathogenesis, combined with 
the rapidly ever‐expanding development of new biotechnologies, combined with existing 
strategies to treat prion diseases, will likely to lead to a feasible and effective treatment for 
prion diseases in the near future. Already, innovations such as genome editing, inhibitory 
RNAs, and improved gene therapy vectors are being applied to and advancing treatment 
strategies to create improved treatments. In addition, strategies that show efficacy that target 
separate components of disease pathogenesis can be combined. Thus, in the coming years, 
the outlook is very promising for the development of an effective treatment and potential 
cure for individuals with prion diseases. Furthermore, strategies used to treat prion diseases 
might be broadly applicable and effective when applied to other protein misfolding diseases. 
The increasing awareness of the role of protein misfolding in many neurodegenerative pro‐
cesses makes the development of an effective treatment strategy for prion diseases a high 
priority.
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